Liver disease represents a major global health issue, with limited availability of effective hepatoprotective treatments. Hojasé or hojasén or Flourensia cernua (Fc) is known for its antioxidant properties and high phenolic content and may exhibit a potential hepatoprotective effect. Additionally, natural products have been shown to restore gut microbiota and reduce liver inflammation. To evaluate the hepatoprotective activity of Fc and its impact on gut microbiota in a valproic acid (VPA)-induced injury model in Wistar rats. Seven groups of Wistar rats (n = 6) were treated as follows: Sham; Non-toxic Fc (NTox 200 and 400 mg/kg); VPA 500 mg/kg; VPA + Fc 200 and VPA + Fc 400; and silybinin 500 mg/kg (VPA + Slb). Liver function tests, malondialdehyde (MDA) and superoxide dismutase (SOD) markers, aerobic gut microbiota analysis, and histological analysis were conducted. No significant differences were observed in ALT and AST levels between NTox 200, NTox 400, and Sham. Only the 400 mg/kg dose of Fc significantly reduced ALT and AST versus VPA, similar to Slb. In VPA + Fc 200 and VPA + Fc 400, MDA and SOD decreased versus VPA, comparable to VPA + Slb. Only VPA + Fc 400 and VPA + Slb restored aerobic gut microbiota versus VPA. No histological changes were observed between groups. Fc extract demonstrated hepatoprotective effects at a dose of 400 mg/kg and impacted the restoration of aerobic gut microbiota against VPA-induced damage.
Renal ischemia–reperfusion (I/R) injury is a major cause of graft dysfunction. Flourensia cernua possesses antioxidant properties that may protect against this injury. This study evaluated its antioxidant capacity and nephroprotective effects in a renal I/R model in Wistar rats. The extract was characterized by phytochemical analysis, total phenolic content, and ABTS, DPPH, and FRAP assays. Hemolytic activity was assessed, and rats were assigned to Sham, Non-Tox, I/R, and I/R + F. cernua groups (200 mg/kg/day for 7 days before I/R). Biochemical parameters, renal oxidative stress markers, and Gpx, Rela, and Mpo expression were evaluated. The extract contained several secondary metabolites, showed radical-scavenging and reducing capacity, and had low hemolytic activity. Pretreatment reduced serum creatinine and renal malondialdehyde levels, restored glutathione and superoxide dismutase activity, and downregulated Gpx expression compared with I/R. Pretreatment with F. cernua partially attenuated I/R-induced renal injury and was associated with reduced lipid peroxidation and preservation of endogenous antioxidant defenses; however, these findings do not establish a causal molecular mechanism.
Left ventricular diastolic dysfunction (LVDD) is a hallmark of cirrhotic cardiomyopathy and has been linked to a poorer quality of life and worse outcomes in patients with end-stage liver disease. Its impact on survival after a liver transplant (LT) is not known, especially when using current diagnostic criteria to define LVDD. We conducted a systematic review and meta-analysis of the current published literature on mortality after a LT in patients with LVDD. We searched for articles in PubMed, Scopus, EMBASE, Web of Science, and the COCHRANE Central database. We included cohort studies that compared post-transplant outcomes between cirrhotic patients with and without LVDD. Our primary outcome of interest was all-cause mortality after a LT in relation to the presence of LVDD per the 2016 American Society of Echocardiography criteria. A total of 1029 articles were screened during the selection process. Two studies included in the meta-analysis showed no significant difference in mortality, but there was high heterogeneity. A narrative review of other studies that classified diastolic function (DD) using different criteria was also performed, revealing an association with worse outcomes in these patients. High-quality prospective studies using current criteria are needed to confirm these findings.